{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:07:50Z","timestamp":1791259670746,"version":"4.1.0"},"reference-count":175,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2015.00230","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T14:20:36Z","timestamp":1431526836000},"source":"Crossref","is-referenced-by-count":66,"title":["Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies"],"prefix":"10.3389","volume":"6","author":[{"given":"Gianfranco","family":"Pittari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Gentilcore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Grivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rutella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/blood-2002-02-0350","article-title":"Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect","volume":"100","author":"Farag","year":"2002","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.smim.2014.02.002","article-title":"Clinical utility of natural killer cells in cancer therapy and transplantation","volume":"26","author":"Knorr","year":"2014","journal-title":"Semin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.4049\/jimmunol.171.6.2977","article-title":"Identification of a novel subpopulation of human cord blood CD34\u00e2\u02c6\u2019CD133\u00e2\u02c6\u2019CD7\u00e2\u02c6\u2019CD45+lineage\u00e2\u02c6\u2019 cells capable of lymphoid\/NK cell differentiation after in vitro exposure to IL-15","volume":"171","author":"Rutella","year":"2003","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.7716543","article-title":"Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells","volume":"268","author":"Colonna","year":"1995","journal-title":"Science"},{"key":"B6","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.4049\/jimmunol.155.5.2306","article-title":"Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes","volume":"155","author":"D\u00e2\u20ac\u2122Andrea","year":"1995","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/1074-7613(95)90025-X","article-title":"Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains","volume":"2","author":"Wagtmann","year":"1995","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1074-7613(00)80300-3","article-title":"Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor","volume":"4","author":"Burshtyn","year":"1996","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13066","DOI":"10.1074\/jbc.272.20.13066","article-title":"A novel phosphotyrosine motif with a critical amino acid at position -2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1","volume":"272","author":"Burshtyn","year":"1997","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1084\/jem.184.1.93","article-title":"Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C","volume":"184","author":"Campbell","year":"1996","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1084\/jem.184.1.295","article-title":"Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C","volume":"184","author":"Fry","year":"1996","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1084\/jem.183.2.645","article-title":"The human leukocyte antigen (HLA)-C-specific \u00e2\u20ac\u0153activatory\u00e2\u20ac\u009d or \u00e2\u20ac\u0153inhibitory\u00e2\u20ac\u009d natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions","volume":"183","author":"Biassoni","year":"1996","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.4049\/jimmunol.158.11.5083","article-title":"Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells","volume":"158","author":"Olcese","year":"1997","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/(SICI)1521-4141(199802)28:02599::AID-IMMU5993.3.CO;2-6","article-title":"Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex","volume":"28","author":"Campbell","year":"1998","journal-title":"Eur J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fimmu.2015.00097","article-title":"NKG2D ligands in tumor immunity: two sides of a coin","volume":"6","author":"Zhang","year":"2015","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/87757","article-title":"Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA","volume":"2","author":"Li","year":"2001","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","article-title":"ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor","volume":"14","author":"Cosman","year":"2001","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1084\/jem.187.12.2065","article-title":"NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis","volume":"187","author":"Vitale","year":"1998","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1084\/jem.190.10.1505","article-title":"Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells","volume":"190","author":"Pende","year":"1999","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/1521-4141(200104)31:41076::AID-IMMU10763.0.CO;2-Y","article-title":"Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin","volume":"31","author":"Pende","year":"2001","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMc1411443","article-title":"Donor activating KIR2DS1 in leukemia","volume":"371","author":"Venstrom","year":"2014","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","article-title":"Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype","volume":"339","author":"Aversa","year":"1998","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.182.2.605","article-title":"Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by \u00e2\u20ac\u0153group 2\u00e2\u20ac\u009d or \u00e2\u20ac\u0153group 1\u00e2\u20ac\u009d NK clones","volume":"182","author":"Biassoni","year":"1995","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1084\/jem.181.3.1133","article-title":"The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor","volume":"181","author":"Gumperz","year":"1995","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1084\/jem.180.2.537","article-title":"NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules","volume":"180","author":"Litwin","year":"1994","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/1074-7613(95)90069-1","article-title":"Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer","volume":"3","author":"Wagtmann","year":"1995","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.4049\/jimmunol.158.9.4026","article-title":"A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes","volume":"158","author":"Winter","year":"1997","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u00e2\u20ac\u02dcmissing self\u00e2\u20ac\u2122: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.4049\/jimmunol.1302517","article-title":"Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia","volume":"192","author":"Cooley","year":"2014","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2014-03-565069","article-title":"KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL","volume":"124","author":"Oevermann","year":"2014","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CCO.0b013e328335a559","article-title":"Biology and clinical effects of natural killer cells in allogeneic transplantation","volume":"22","author":"Benjamin","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/bmt.2009.265","article-title":"Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients","volume":"45","author":"Pittari","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","article-title":"Depletion of T-cell receptor \u00ce\u00b1\u00ce\u00b2 and CD19 positive cells from apheresis products with the Clini-MACS device","volume":"15","author":"Schumm","year":"2013","journal-title":"Cytotherapy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12967-014-0240-z","article-title":"Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-\u00ce\u00b1\u00ce\u00b2\/CD19-depleted haploidentical stem cell grafts","volume":"12","author":"Rutella","year":"2014","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/(SICI)1521-4141(199809)28:092854::AID-IMMU28543.0.CO;2-W","article-title":"HLA-E-bound peptides influence recognition by inhibitory and triggering CD94\/NKG2 receptors: preferential response to an HLA-G-derived nonamer","volume":"28","author":"Llano","year":"1998","journal-title":"Eur J Immunol"},{"key":"B40","first-page":"4420","article-title":"Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor","volume":"41","author":"Lotze","year":"1981","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4049\/jimmunol.125.1.238","article-title":"In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors","volume":"125","author":"Yron","year":"1980","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","article-title":"Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes","volume":"155","author":"Grimm","year":"1982","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1987.5.12.1933","article-title":"In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy","volume":"5","author":"Phillips","year":"1987","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1084\/jem.164.3.814","article-title":"Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis","volume":"164","author":"Phillips","year":"1986","journal-title":"J Exp Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1479-5876-8-129","article-title":"Thymoglobulin, interferon-\u00ce\u00b3 and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures","volume":"8","author":"Bonanno","year":"2010","journal-title":"J Transl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1479-5876-11-83","article-title":"Cytokine-induced killer cells promote antitumor immunity","volume":"11","author":"Jiang","year":"2013","journal-title":"J Transl Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.intimp.2008.12.001","article-title":"Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model","volume":"9","author":"Kim","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"12044","DOI":"10.1073\/pnas.96.21.12044","article-title":"Visualizing the kinetics of tumor-cell clearance in living animals","volume":"96","author":"Sweeney","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B50","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S1083-8791(01)70014-6","article-title":"Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma","volume":"7","author":"Verneris","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1182\/blood-2002-06-1751","article-title":"Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging","volume":"101","author":"Edinger","year":"2003","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1537-2995.2012.03724.x","article-title":"Natural killer cells: a review of manufacturing and clinical utility","volume":"53","author":"Koepsell","year":"2013","journal-title":"Transfusion"},{"key":"B53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fimmu.2014.00095","article-title":"Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies","volume":"5","author":"Chouaib","year":"2014","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood.V90.8.3098","article-title":"Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections","volume":"90","author":"Miller","year":"1997","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e20740","DOI":"10.1371\/journal.pone.0020740","article-title":"Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process","volume":"6","author":"Spanholtz","year":"2011","journal-title":"PLoS One"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/leu.2011.345","article-title":"Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells","volume":"26","author":"Tanaka","year":"2012","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1537-2995.2006.01145.x","article-title":"Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience","volume":"47","author":"McKenna","year":"2007","journal-title":"Transfusion"},{"key":"B59","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14653240310003558","article-title":"Purification of human natural killer cells using a clinical-scale immunomagnetic method","volume":"5","author":"Iyengar","year":"2003","journal-title":"Cytotherapy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3109\/14653249.2010.504770","article-title":"Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor","volume":"12","author":"Sutlu","year":"2010","journal-title":"Cytotherapy"},{"key":"B62","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/15258160260194794","article-title":"Large-scale generation of natural killer lymphocytes for clinical application","volume":"11","author":"Luhm","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"B64","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14653240310001523","article-title":"Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy","volume":"5","author":"Tam","year":"2003","journal-title":"Cytotherapy"},{"key":"B65","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3109\/14653241003786155","article-title":"Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients","volume":"12","author":"Siegler","year":"2010","journal-title":"Cytotherapy"},{"key":"B66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14653240310004548","article-title":"Ex vivo expansion of natural killer cells for clinical applications","volume":"6","author":"Klingemann","year":"2004","journal-title":"Cytotherapy"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"B70","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/sj.bmt.1703406","article-title":"Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children","volume":"29","author":"Lang","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/blood-2007-09-110312","article-title":"Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components","volume":"111","author":"Alici","year":"2008","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/bmt.2009.304","article-title":"Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study","volume":"45","author":"Yoon","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B73","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B74","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","article-title":"Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation","volume":"143","author":"Shi","year":"2008","journal-title":"Br J Haematol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00262-010-0896-z","article-title":"Allogeneic natural killer cells for refractory lymphoma","volume":"59","author":"Bachanova","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B77","first-page":"2320","article-title":"Preliminary results of a phase 1\/2 clinical trial of CNDO-109-activated allogeneic natural killer cells in high risk acute myelogenous leukemia patients in first complete remission","volume":"124","author":"Fehniger","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B78","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1537-2995.2012.03764.x","article-title":"Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions","volume":"53","author":"Klingemann","year":"2013","journal-title":"Transfusion"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0198-8859(01)00313-5","article-title":"A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells","volume":"62","author":"Carlens","year":"2001","journal-title":"Hum Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1479-5876-10-247","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma","volume":"10","author":"Bonanno","year":"2012","journal-title":"J Transl Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bbmt.2012.08.018","article-title":"Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+ T cells after autologous transplantation for myeloma","volume":"19","author":"Meehan","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B82","first-page":"4035","article-title":"Nicotinamide, a form of vitamin B3, promotes expansion of natural killer cells that display increased in vivo survival and cytotoxic activity","volume":"118","author":"Frei","year":"2011","journal-title":"ASH Annuual Meeting Abstracts"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e53611","DOI":"10.1371\/journal.pone.0053611","article-title":"GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo","volume":"8","author":"Lim","year":"2013","journal-title":"PLoS One"},{"key":"B84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fonc.2013.00118","article-title":"Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol","volume":"3","author":"Koehl","year":"2013","journal-title":"Front Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1537-2995.2008.01969.x","article-title":"Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation","volume":"49","author":"Meyer-Monard","year":"2009","journal-title":"Transfusion"},{"key":"B86","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1055\/s-2005-872520","article-title":"Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children","volume":"217","author":"Koehl","year":"2005","journal-title":"Klin Padiatr"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcyt.2014.04.008","article-title":"Effect of exposure to interleukin-21 at various time points on human natural killer cell culture","volume":"16","author":"Lim","year":"2014","journal-title":"Cytotherapy"},{"key":"B88","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.V114.22.463.463","article-title":"In vitro expanded NK cells have increased natural cytotoxity receptors, TRAIL and NKG2D expression, and superior tumor cytotoxicity compared to short-term IL-2-activated NK cells","volume":"114","author":"Berg","year":"2009","journal-title":"Blood"},{"issue":"2","key":"B89","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00262-014-1614-z","article-title":"Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients","volume":"64","author":"Peragine","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"231\u00e2\u20ac\u201c41","key":"B90","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jcyt.2012.10.019","article-title":"Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers","volume":"15","author":"Kim","year":"2013","journal-title":"Cytotherapy"},{"key":"B91","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.4049\/jimmunol.1202120","article-title":"NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand","volume":"190","author":"Pittari","year":"2013","journal-title":"J Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1365-2141.2009.07667.x","article-title":"Replicative potential of human natural killer cells","volume":"145","author":"Fujisaki","year":"2009","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"key":"B94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jcyt.2014.08.003","article-title":"Differential activation of cord blood and peripheral blood natural killer cells by cytokines","volume":"17","author":"Alnabhan","year":"2015","journal-title":"Cytotherapy"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcyt.2014.12.001","article-title":"Cord blood: a promising source of allogeneic natural killer cells for immunotherapy","volume":"17","author":"Shaim","year":"2015","journal-title":"Cytotherapy"},{"key":"B96","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbmt.2014.10.014","article-title":"Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture","volume":"21","author":"Tomchuck","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e64384","DOI":"10.1371\/journal.pone.0064384","article-title":"Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD\/SCID\/IL2R\u00ce\u00b3(null) mice","volume":"8","author":"Cany","year":"2013","journal-title":"PLoS One"},{"key":"B98","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e109352","DOI":"10.1371\/journal.pone.0109352","article-title":"Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis","volume":"9","author":"Cho","year":"2014","journal-title":"PLoS One"},{"key":"B102","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","article-title":"Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15","volume":"124","author":"Imamura","year":"2014","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.exphem.2005.07.006","article-title":"Efficient gene transfer into primary human natural killer cells by retroviral transduction","volume":"33","author":"Guven","year":"2005","journal-title":"Exp Hematol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11684-012-0177-7","article-title":"Natural killer cell lines in tumor immunotherapy","volume":"6","author":"Cheng","year":"2012","journal-title":"Front Med"},{"key":"B108","first-page":"68","article-title":"A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood","volume":"2","author":"Klingemann","year":"1996","journal-title":"Biol Blood Marrow Transplant"},{"key":"B109","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"B110","first-page":"2859","article-title":"Antileukemia activity of a natural killer cell line against human leukemias","volume":"4","author":"Yan","year":"1998","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/106161299320316","article-title":"Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92","volume":"8","author":"Tam","year":"1999","journal-title":"J Hematother"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/10430349950018030","article-title":"Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy","volume":"10","author":"Tam","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B113","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.4049\/jimmunol.129.3.1299","article-title":"Generation of a cloned NK cell line derived from the \u00e2\u20ac\u0153null cell\u00e2\u20ac\u009d fraction of human peripheral blood","volume":"129","author":"Hercend","year":"1982","journal-title":"J Immunol"},{"key":"B114","first-page":"171","article-title":"Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines","volume":"6","author":"Perussia","year":"1987","journal-title":"Nat Immun Cell Growth Regul"},{"key":"B115","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/0008-8749(91)90290-R","article-title":"Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells","volume":"135","author":"Rabinowich","year":"1991","journal-title":"Cell Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/0959-8049(94)90460-X","article-title":"Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2","volume":"30A","author":"Escudier","year":"1994","journal-title":"Eur J Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1158\/0008-5472.CAN-06-0680","article-title":"Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity","volume":"66","author":"Lundqvist","year":"2006","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.4049\/jimmunol.0902856","article-title":"Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells","volume":"184","author":"Lundqvist","year":"2010","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3324\/haematol.2011.056747","article-title":"Highly activated and expanded natural killer cells for multiple myeloma immunotherapy","volume":"97","author":"Garg","year":"2012","journal-title":"Haematologica"},{"key":"B121","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cellimm.2014.04.011","article-title":"Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21","volume":"290","author":"Jiang","year":"2014","journal-title":"Cell Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","article-title":"Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/1538-7445.AM10-1271","article-title":"In vitro expanded natural killer (NK) cells are more susceptible to Fas-mediated apoptosis compared to fresh and overnight IL-2 activated NK cells","volume":"70","author":"Betters","year":"2010","journal-title":"Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3791\/2540","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","volume":"pii","author":"Somanchi","year":"2011","journal-title":"J Vis Exp"},{"key":"B126","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.1182\/blood-2011-11-389924","article-title":"Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7","volume":"119","author":"Somanchi","year":"2012","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","article-title":"Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy","volume":"20","author":"Miller","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"B131","first-page":"283","article-title":"Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial","volume":"16","author":"Benyunes","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B132","first-page":"607","article-title":"Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period","volume":"1","author":"Lister","year":"1995","journal-title":"Clin Cancer Res"},{"key":"B133","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1200\/JCO.1991.9.12.2110","article-title":"Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity","volume":"9","author":"Caligiuri","year":"1991","journal-title":"J Clin Oncol"},{"key":"B134","first-page":"34","article-title":"Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity","volume":"3","author":"Miller","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"B135","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V79.2.517.517","article-title":"Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation","volume":"79","author":"Soiffer","year":"1992","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/JCI116161","article-title":"Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2","volume":"91","author":"Caligiuri","year":"1993","journal-title":"J Clin Invest"},{"key":"B137","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1084\/jem.170.1.291","article-title":"Activation of natural killer cells via the p75 interleukin 2 receptor","volume":"170","author":"Phillips","year":"1989","journal-title":"J Exp Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bmt.1704086","article-title":"IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I\/II trial","volume":"32","author":"Burns","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B139","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1615\/CritRevOncog.2014011091","article-title":"NK cells in therapy of cancer","volume":"19","author":"Bachanova","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"B140","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/358066a0","article-title":"MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells","volume":"358","author":"Karlhofer","year":"1992","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"key":"B142","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1479-5876-10-48","article-title":"New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer","volume":"10","author":"Stroncek","year":"2012","journal-title":"J Transl Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"383","DOI":"10.7150\/jca.2.383","article-title":"Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells","volume":"2","author":"Lundqvist","year":"2011","journal-title":"J Cancer"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.bbmt.2010.02.018","article-title":"Natural killer cell-enriched donor lymphocyte infusions from A 3-6\/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation","volume":"16","author":"Rizzieri","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B145","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-myeloma activity of natural killer lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br J Haematol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bcmd.2004.08.013","article-title":"IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation","volume":"33","author":"Koehl","year":"2004","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"B148","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T cell depleted stem cell transplantation","volume":"125","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood-2014-12-616359","article-title":"The off-target effects of nonspecific NK cells","volume":"125","author":"Lee","year":"2015","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Benson","year":"2012","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2009-02-206532","article-title":"Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells","volume":"114","author":"Romagne","year":"2009","journal-title":"Blood"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"B158","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jcyt.2014.01.003","article-title":"Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion","volume":"16","author":"Rettinger","year":"2014","journal-title":"Cytotherapy"},{"key":"B159","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bmt.1705503","article-title":"Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation","volume":"38","author":"Introna","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"B160","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jcyt.2014.09.006","article-title":"Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood","volume":"17","author":"Zhang","year":"2015","journal-title":"Cytotherapy"},{"key":"B161","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jcyt.2013.12.010","article-title":"Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines","volume":"16","author":"Durrieu","year":"2014","journal-title":"Cytotherapy"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.bbmt.2010.05.015","article-title":"Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation","volume":"16","author":"Introna","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B163","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12013-011-9273-6","article-title":"Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma","volume":"62","author":"Lu","year":"2012","journal-title":"Cell Biochem Biophys"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","article-title":"Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma","volume":"81","author":"Schmidt-Wolf","year":"1999","journal-title":"Br J Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jcyt.2013.11.001","article-title":"Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells","volume":"16","author":"Yang","year":"2014","journal-title":"Cytotherapy"},{"key":"B166","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hon.886","article-title":"Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial","volume":"27","author":"Olioso","year":"2009","journal-title":"Hematol Oncol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","article-title":"Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)","volume":"137","author":"Hontscha","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"B168","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00432-014-1864-3","article-title":"Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC)","volume":"141","author":"Schmeel","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12094-012-0768-4","article-title":"Review of Chinese clinical trials on CIK cell treatment for malignancies","volume":"14","author":"Li","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/bmt.2011.202","article-title":"The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies","volume":"47","author":"Linn","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B171","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3109\/14653249.2012.681038","article-title":"Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol","volume":"14","author":"Rutella","year":"2012","journal-title":"Cytotherapy"},{"key":"B172","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrclinonc.2014.177","article-title":"Immune-based therapies for childhood cancer","volume":"11","author":"Mackall","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B173","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V80.9.2221.2221","article-title":"Role of monocytes in the expansion of human activated natural killer cells","volume":"80","author":"Miller","year":"1992","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u00ce\u00b1\u00ce\u00b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"key":"B175","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2217\/imt.12.89","article-title":"Is there a role for cytokine-induced killer cells in cancer immunotherapy?","volume":"4","author":"Rutella","year":"2012","journal-title":"Immunotherapy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T13:17:22Z","timestamp":1691673442000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.frontiersin.org\/NK_Cell_Biology\/10.3389\/fimmu.2015.00230\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,13]]},"references-count":175,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2015.00230","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,13]]}}}